301126 达嘉维康
已收盘 07-29 15:00:00
资讯
新帖
简况
达嘉维康:嘉辰医院正积极推进辅助生殖许可资质申办
证券之星 · 07-24
达嘉维康:嘉辰医院正积极推进辅助生殖许可资质申办
达嘉维康:截止2025年7月18日公司股东人数为15,969人
证券之星 · 07-22
达嘉维康:截止2025年7月18日公司股东人数为15,969人
达嘉维康:监事唐娟2025年6月10日至7月3日减持48500股
证券之星 · 07-17
达嘉维康:监事唐娟2025年6月10日至7月3日减持48500股
达嘉维康:截止7月10日股东人数为16011人
证券之星 · 07-16
达嘉维康:截止7月10日股东人数为16011人
达嘉维康:部分在研产品依折麦布阿托伐他汀钙片已完成稳定性研究及BE试验
证券之星 · 07-16
达嘉维康:部分在研产品依折麦布阿托伐他汀钙片已完成稳定性研究及BE试验
达嘉维康高速扩店连续三年增收减利 11.35亿商誉压顶仍推溢价28倍收购
长江商报 · 07-15
达嘉维康高速扩店连续三年增收减利 11.35亿商誉压顶仍推溢价28倍收购
达嘉维康最新公告:拟收购安徽达嘉维康健康大药房有限公司60.85%股权
证券之星 · 07-11
达嘉维康最新公告:拟收购安徽达嘉维康健康大药房有限公司60.85%股权
达嘉维康:公司部分在研产品依折麦布阿托伐他汀钙片已完成稳定性研究及BE试验
证券之星 · 07-08
达嘉维康:公司部分在研产品依折麦布阿托伐他汀钙片已完成稳定性研究及BE试验
达嘉维康:7月3日高管唐娟减持股份合计3000股
证券之星 · 07-04
达嘉维康:7月3日高管唐娟减持股份合计3000股
达嘉维康:7月2日高管唐娟减持股份合计1.85万股
证券之星 · 07-03
达嘉维康:7月2日高管唐娟减持股份合计1.85万股
达嘉维康:东方丽君系列有洗发水、护发素、育发液等产品
证券之星 · 06-19
达嘉维康:东方丽君系列有洗发水、护发素、育发液等产品
达嘉维康:6月17日高管唐娟减持股份合计3000股
证券之星 · 06-18
达嘉维康:6月17日高管唐娟减持股份合计3000股
每周股票复盘:达嘉维康(301126)监事与高管减持股份,股东户数减少
证券之星 · 06-14
每周股票复盘:达嘉维康(301126)监事与高管减持股份,股东户数减少
达嘉维康:6月10日高管唐娟减持股份合计2.4万股
证券之星 · 06-11
达嘉维康:6月10日高管唐娟减持股份合计2.4万股
达嘉维康:6月6日高管李玉兰减持股份合计5000股
证券之星 · 06-09
达嘉维康:6月6日高管李玉兰减持股份合计5000股
达嘉维康:公司积极探索与各大高校、医院等科研机构合作
证券之星 · 06-06
达嘉维康:公司积极探索与各大高校、医院等科研机构合作
达嘉维康新注册《达嘉维康医保结算平台V1.0.0》项目的软件著作权
证券之星 · 05-24
达嘉维康新注册《达嘉维康医保结算平台V1.0.0》项目的软件著作权
达嘉维康:3位董监高股东基于个人资金需求计划减持不超过148,500股
证券之星 · 05-21
达嘉维康:3位董监高股东基于个人资金需求计划减持不超过148,500股
达嘉维康(301126.SZ)部分董监高拟合计减持不超14.85万股
智通财经 · 05-14
达嘉维康(301126.SZ)部分董监高拟合计减持不超14.85万股
达嘉维康:公司相关收购标的进展按协议正常推进
证券之星 · 04-30
达嘉维康:公司相关收购标的进展按协议正常推进
加载更多
公司概况
公司名称:
湖南达嘉维康医药产业股份有限公司
所属行业:
批发业
上市日期:
2021-12-07
主营业务:
湖南达嘉维康医药产业股份有限公司的主营业务是药品、生物制品、医疗器械等产品的分销及零售业务。公司的主要产品是抗肿瘤药、免疫调节用药、心脑血管用药、呼吸系统用药、抗病毒用药、化学药制剂、中成药、生物制药、医疗器械、非药品、中药饮片、清热散结胶囊、脑得生丸、障眼明胶囊、舒筋活血胶囊、清热解毒类、心脑血管类、泌尿类。
发行价格:
12.37
{"stockData":{"symbol":"301126","market":"SZ","secType":"STK","nameCN":"达嘉维康","latestPrice":11.81,"timestamp":1753772634000,"preClose":11.97,"halted":0,"volume":12833985,"delay":0,"changeRate":-0.0134,"floatShares":138000000,"shares":204999999,"eps":0.0501,"marketStatus":"已收盘","change":-0.16,"latestTime":"07-29 15:00:00","open":12.39,"high":12.72,"low":11.79,"amount":154000000,"amplitude":0.0777,"askPrice":11.82,"askSize":21,"bidPrice":11.81,"bidSize":1674,"shortable":0,"etf":0,"ttmEps":0.0501,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1753839000000},"marketStatusCode":5,"adr":0,"adjPreClose":11.97,"symbolType":"stock","openAndCloseTimeList":[[1753752600000,1753759800000],[1753765200000,1753772400000]],"highLimit":13.17,"lowLimit":10.77,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":205403200,"isCdr":false,"pbRate":1.4,"roa":"--","peRate":235.728543,"roe":"0.18%","epsLYR":0.13,"committee":0.700691,"marketValue":2426000000,"turnoverRate":0.0931,"status":1,"floatMarketCap":1628000000},"requestUrl":"/m/hq/s/301126","defaultTab":"news","newsList":[{"id":"2553221645","title":"达嘉维康:嘉辰医院正积极推进辅助生殖许可资质申办","url":"https://stock-news.laohu8.com/highlight/detail?id=2553221645","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2553221645?lang=zh_cn&edition=full","pubTime":"2025-07-24 09:01","pubTimestamp":1753318883,"startTime":"0","endTime":"0","summary":"证券之星消息,达嘉维康(301126)07月23日在投资者关系平台上答复投资者关心的问题。投资者提问:董秘:请问公司辅助生殖牌照申请进展如何?达嘉维康回复:您好,公司旗下子公司嘉辰医院正在积极推进申办人类辅助生殖许可资质,由于辅助生殖技术壁垒高,牌照申请流程长、审批标准严格,对公司持续开展辅助生殖业务前景存在不确定性。感谢您的关注!以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025072400005833.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0250","301126"],"gpt_icon":0},{"id":"2553807652","title":"达嘉维康:截止2025年7月18日公司股东人数为15,969人","url":"https://stock-news.laohu8.com/highlight/detail?id=2553807652","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2553807652?lang=zh_cn&edition=full","pubTime":"2025-07-22 15:48","pubTimestamp":1753170492,"startTime":"0","endTime":"0","summary":"证券之星消息,达嘉维康(301126)07月22日在投资者关系平台上答复投资者关心的问题。投资者提问:尊敬的董秘 你好 衷心感谢你们不厌其烦回答投资者的提问。请问贵公司2025年7月20日A股股东人数是多少?谢谢达嘉维康回复:您好,截止2025年7月18日,公司股东人数为15,969人。感谢您的关注!以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025072200021014.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0250","301126"],"gpt_icon":0},{"id":"2552903481","title":"达嘉维康:监事唐娟2025年6月10日至7月3日减持48500股","url":"https://stock-news.laohu8.com/highlight/detail?id=2552903481","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2552903481?lang=zh_cn&edition=full","pubTime":"2025-07-17 20:51","pubTimestamp":1752756715,"startTime":"0","endTime":"0","summary":"证券之星消息,达嘉维康07月16日在投资者关系平台上答复投资者关心的问题。投资者提问:尊敬的董秘您好,唐娟监事2025/06/10至2025/07/03的持股变动数贵公司公告披露与交易所严重不符,请问贵公司公告和交易所哪个数据准确?达嘉维康回复:您好,公司监事唐娟在2025/6/10-2025/7/3区间共计减持48500股,具体减持情况如下:2025/6/10,减持24000股,交易均价为11.36元;2025/6/17,减持3000股,交易均价为11.23元;2025/7/2,减持18500股,交易均价为11.36元;2025/7/3,减持3000股,交易均价为11.36元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025071700035271.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0250","301126"],"gpt_icon":0},{"id":"2551327111","title":"达嘉维康:截止7月10日股东人数为16011人","url":"https://stock-news.laohu8.com/highlight/detail?id=2551327111","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2551327111?lang=zh_cn&edition=full","pubTime":"2025-07-16 11:36","pubTimestamp":1752637013,"startTime":"0","endTime":"0","summary":"证券之星消息,达嘉维康(301126)07月15日在投资者关系平台上答复投资者关心的问题。投资者提问:董秘您好!请问截止7月10号,公司的股东人数是多少?谢谢达嘉维康回复:您好,截止2025年7月10日,公司股东人数为16011人。感谢您的关注!以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025071600015257.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301126","BK0250"],"gpt_icon":0},{"id":"2551111387","title":"达嘉维康:部分在研产品依折麦布阿托伐他汀钙片已完成稳定性研究及BE试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2551111387","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2551111387?lang=zh_cn&edition=full","pubTime":"2025-07-16 11:36","pubTimestamp":1752637010,"startTime":"0","endTime":"0","summary":"证券之星消息,达嘉维康07月15日在投资者关系平台上答复投资者关心的问题。公司部分在研产品依折麦布阿托伐他汀钙片已完成稳定性研究及BE试验;沙库巴曲缬沙坦钠片进入技术审评阶段;阿奇霉素干混悬剂发补研究中,诺氟沙星胶囊正在进行中试研究;诺氟沙星原料药正在进行中试研究。具体研发进展敬请关注公司发布的相关公告。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025071600015253.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0250","301126"],"gpt_icon":0},{"id":"2551131576","title":"达嘉维康高速扩店连续三年增收减利 11.35亿商誉压顶仍推溢价28倍收购","url":"https://stock-news.laohu8.com/highlight/detail?id=2551131576","media":"长江商报","labels":["merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2551131576?lang=zh_cn&edition=full","pubTime":"2025-07-15 08:10","pubTimestamp":1752538226,"startTime":"0","endTime":"0","summary":"本次交易中,安徽达嘉维康整体估值为1.9亿元,增值率高达2776.97%。3个月后,安徽达嘉维康实施减资,注册资本由1亿元减少为800万元,各股东同比例减资。以2025年4月30日为基准日,安徽达嘉维康股东全部权益评估值为1.9亿元,较其所有者权益账面价值增加1.84亿元,增值率高达2776.97%。高速扩张门店三年增10.5倍收购安徽达嘉维康,达嘉维康意在进一步拓展业务版图。上市次年即2022年,达嘉维康的净利润下降,并已连续三年增收不增利。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.jrj.com.cn/2025/07/15081051690109.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["301126","BK0250"],"gpt_icon":0},{"id":"2550958799","title":"达嘉维康最新公告:拟收购安徽达嘉维康健康大药房有限公司60.85%股权","url":"https://stock-news.laohu8.com/highlight/detail?id=2550958799","media":"证券之星","labels":["shareholding","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2550958799?lang=zh_cn&edition=full","pubTime":"2025-07-11 19:51","pubTimestamp":1752234669,"startTime":"0","endTime":"0","summary":"达嘉维康(301126.SZ)公告称,公司拟以自有资金或自筹资金收购安徽达嘉维康健康大药房有限公司60.85%的股权,交易价格为11,561.50万元。交易完成后,安徽达嘉维康将成为公司控股子公司,纳入公司合并报表范围。此次交易构成关联交易,公司董事会已审议通过该议案,并授权公司董事长签署相关合同文件。以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025071100035683.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,merge","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301126","BK0250"],"gpt_icon":0},{"id":"2549614435","title":"达嘉维康:公司部分在研产品依折麦布阿托伐他汀钙片已完成稳定性研究及BE试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2549614435","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2549614435?lang=zh_cn&edition=full","pubTime":"2025-07-08 08:40","pubTimestamp":1751935224,"startTime":"0","endTime":"0","summary":"证券之星消息,达嘉维康07月07日在投资者关系平台上答复投资者关心的问题。公司部分在研产品依折麦布阿托伐他汀钙片已完成稳定性研究及BE试验;沙库巴曲缬沙坦钠片进入技术审评阶段;阿奇霉素干混悬剂发补研究中,诺氟沙星胶囊正在进行中试研究;诺氟沙星原料药正在进行中试研究。具体研发进展敬请关注公司发布的相关公告。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025070800006545.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301126","BK0250"],"gpt_icon":0},{"id":"2548239930","title":"达嘉维康:7月3日高管唐娟减持股份合计3000股","url":"https://stock-news.laohu8.com/highlight/detail?id=2548239930","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2548239930?lang=zh_cn&edition=full","pubTime":"2025-07-04 21:03","pubTimestamp":1751634203,"startTime":"0","endTime":"0","summary":"证券之星消息,根据7月4日市场公开信息、上市公司公告及交易所披露数据整理,达嘉维康最新董监高及相关人员股份变动情况:2025年7月3日公司监事唐娟共减持公司股份3000.0股,占公司总股本为0.0015%。达嘉维康近半年内的董监高及核心技术人员增减持详情如下:达嘉维康的高管列表及最新持股情况如下:融资融券数据显示该股近5日融资净流出222.86万,融资余额减少;融券净流入0.0,融券余额增加。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025070400036304.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301126","BK0250"],"gpt_icon":0},{"id":"2548980248","title":"达嘉维康:7月2日高管唐娟减持股份合计1.85万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2548980248","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2548980248?lang=zh_cn&edition=full","pubTime":"2025-07-03 21:02","pubTimestamp":1751547736,"startTime":"0","endTime":"0","summary":"证券之星消息,根据7月3日市场公开信息、上市公司公告及交易所披露数据整理,达嘉维康最新董监高及相关人员股份变动情况:2025年7月2日公司监事唐娟共减持公司股份1.85万股,占公司总股本为0.009%。达嘉维康近半年内的董监高及核心技术人员增减持详情如下:达嘉维康的高管列表及最新持股情况如下:融资融券数据显示该股近5日融资净流出275.14万,融资余额减少;融券净流入0.0,融券余额增加。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025070300036651.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301126","BK0250"],"gpt_icon":0},{"id":"2544846401","title":"达嘉维康:东方丽君系列有洗发水、护发素、育发液等产品","url":"https://stock-news.laohu8.com/highlight/detail?id=2544846401","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2544846401?lang=zh_cn&edition=full","pubTime":"2025-06-19 08:49","pubTimestamp":1750294149,"startTime":"0","endTime":"0","summary":"证券之星消息,达嘉维康(301126)06月18日在投资者关系平台上答复投资者关心的问题。投资者提问:公司产品东方丽君防脱育发对五十岁以上人群还有效果吗?达嘉维康回复:投资者您好,东方丽君系列有洗发水、护发素、育发液等产品,其中育发液产品有一定的防脱、生发、调节头皮环境的作用。感谢您的关注!以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025061900003937.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0250","301126"],"gpt_icon":0},{"id":"2544997038","title":"达嘉维康:6月17日高管唐娟减持股份合计3000股","url":"https://stock-news.laohu8.com/highlight/detail?id=2544997038","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2544997038?lang=zh_cn&edition=full","pubTime":"2025-06-18 21:02","pubTimestamp":1750251763,"startTime":"0","endTime":"0","summary":"证券之星消息,根据6月18日市场公开信息、上市公司公告及交易所披露数据整理,达嘉维康最新董监高及相关人员股份变动情况:2025年6月17日公司监事唐娟共减持公司股份3000.0股,占公司总股本为0.0015%。达嘉维康近半年内的董监高及核心技术人员增减持详情如下:达嘉维康的高管列表及最新持股情况如下:融资融券数据显示该股近5日融资净流入232.56万,融资余额增加;融券净流入0.0,融券余额增加。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025061800035843.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301126","BK0250"],"gpt_icon":0},{"id":"2543574986","title":"每周股票复盘:达嘉维康(301126)监事与高管减持股份,股东户数减少","url":"https://stock-news.laohu8.com/highlight/detail?id=2543574986","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2543574986?lang=zh_cn&edition=full","pubTime":"2025-06-14 12:28","pubTimestamp":1749875295,"startTime":"0","endTime":"0","summary":"截至2025年6月13日收盘,达嘉维康报收于10.86元,较上周的11.09元下跌2.07%。本周,达嘉维康6月10日盘中最高价报11.42元。根据6月9日市场公开信息、上市公司公告及交易所披露数据整理,达嘉维康最新董监高及相关人员股份变动情况:2025年6月6日公司高管李玉兰共减持公司股份5000.0股,占公司总股本为0.0024%。近日达嘉维康披露,截至2025年5月30日公司股东户数为1.6万户,较4月18日减少387.0户,减幅为2.36%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025061400011902.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0250","301126"],"gpt_icon":0},{"id":"2542286582","title":"达嘉维康:6月10日高管唐娟减持股份合计2.4万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2542286582","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2542286582?lang=zh_cn&edition=full","pubTime":"2025-06-11 21:02","pubTimestamp":1749646927,"startTime":"0","endTime":"0","summary":"证券之星消息,根据6月11日市场公开信息、上市公司公告及交易所披露数据整理,达嘉维康最新董监高及相关人员股份变动情况:2025年6月10日公司监事唐娟共减持公司股份2.4万股,占公司总股本为0.0117%。达嘉维康近半年内的董监高及核心技术人员增减持详情如下:达嘉维康的高管列表及最新持股情况如下:融资融券数据显示该股近5日融资净流入267.73万,融资余额增加;融券净流入0.0,融券余额增加。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025061100035714.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301126","BK0250"],"gpt_icon":0},{"id":"2542038785","title":"达嘉维康:6月6日高管李玉兰减持股份合计5000股","url":"https://stock-news.laohu8.com/highlight/detail?id=2542038785","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2542038785?lang=zh_cn&edition=full","pubTime":"2025-06-09 21:02","pubTimestamp":1749474135,"startTime":"0","endTime":"0","summary":"证券之星消息,根据6月9日市场公开信息、上市公司公告及交易所披露数据整理,达嘉维康最新董监高及相关人员股份变动情况:2025年6月6日公司高管李玉兰共减持公司股份5000.0股,占公司总股本为0.0024%。达嘉维康近半年内的董监高及核心技术人员增减持详情如下:达嘉维康的高管列表及最新持股情况如下:融资融券数据显示该股近5日融资净流入282.41万,融资余额增加;融券净流入0.0,融券余额增加。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025060900031543.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301126","BK0250"],"gpt_icon":0},{"id":"2541310328","title":"达嘉维康:公司积极探索与各大高校、医院等科研机构合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2541310328","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2541310328?lang=zh_cn&edition=full","pubTime":"2025-06-06 16:30","pubTimestamp":1749198640,"startTime":"0","endTime":"0","summary":"证券之星消息,达嘉维康06月06日在投资者关系平台上答复投资者关心的问题。公司旗下子公司嘉辰医院正在积极推进申办人类辅助生殖许可资质,由于辅助生殖技术壁垒高,牌照申请流程长、审批标准严格,对公司持续开展辅助生殖业务前景存在不确定性。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025060600024411.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0250","301126"],"gpt_icon":0},{"id":"2538194259","title":"达嘉维康新注册《达嘉维康医保结算平台V1.0.0》项目的软件著作权","url":"https://stock-news.laohu8.com/highlight/detail?id=2538194259","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2538194259?lang=zh_cn&edition=full","pubTime":"2025-05-25 01:40","pubTimestamp":1748108421,"startTime":"0","endTime":"0","summary":"证券之星消息,近日达嘉维康(301126)新注册了《达嘉维康医保结算平台V1.0.0》项目的软件著作权。今年以来达嘉维康新注册软件著作权1个。结合公司2024年年报财务数据,2024年公司在研发方面投入了1625.78万元,同比增126.64%。数据来源:企查查以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025052500000105.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0250","301126"],"gpt_icon":0},{"id":"2537933134","title":"达嘉维康:3位董监高股东基于个人资金需求计划减持不超过148,500股","url":"https://stock-news.laohu8.com/highlight/detail?id=2537933134","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2537933134?lang=zh_cn&edition=full","pubTime":"2025-05-21 20:53","pubTimestamp":1747832024,"startTime":"0","endTime":"0","summary":"证券之星消息,达嘉维康05月20日在投资者关系平台上答复投资者关心的问题。达嘉维康回复:投资者您好,公司在2025年5月14日披露了《关于董事、监事、高级管理人员减持股份的预披露公告》,本次减持股东为公司董事、监事、高管人员,并非公司实控人、控股股东,减持主体符合《上市公司股东减持股份管理暂行办法》的要求。3位董监高股东均基于个人资金需求,计划减持数量合计不超过148,500股,占公司总股本的0.072%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025052100037395.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301126","BK0250"],"gpt_icon":0},{"id":"2535786029","title":"达嘉维康(301126.SZ)部分董监高拟合计减持不超14.85万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2535786029","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2535786029?lang=zh_cn&edition=full","pubTime":"2025-05-14 20:31","pubTimestamp":1747225897,"startTime":"0","endTime":"0","summary":"智通财经APP讯,达嘉维康(301126.SZ)公告,公司董事、高级管理人员陈珊瑚、监事唐娟和高级管理人员李玉兰计划合计减持公司股份数量不超过14.85万股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1293253.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["301126","BK0250"],"gpt_icon":0},{"id":"2531745525","title":"达嘉维康:公司相关收购标的进展按协议正常推进","url":"https://stock-news.laohu8.com/highlight/detail?id=2531745525","media":"证券之星","labels":["merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2531745525?lang=zh_cn&edition=full","pubTime":"2025-04-30 08:39","pubTimestamp":1745973556,"startTime":"0","endTime":"0","summary":"证券之星消息,达嘉维康(301126)04月29日在投资者关系平台上答复投资者关心的问题。投资者提问:公司第四季度为什么会出现大幅亏损,高价收购资产有三家未完成承诺,有没按合同进行索赔。达嘉维康回复:您好,公司相关收购标的进展按协议正常推进,目前部分已履行完毕,部分尚在承诺期内,公司经营具体情况详细内容情况可见公司于2025年4月21日披露的《2024年年度报告》,感谢您的关注!以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025043000011909.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301126","BK0250"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1753797957625,"stockEarnings":[{"period":"1week","weight":0.0008},{"period":"1month","weight":0.0982},{"period":"3month","weight":0.1962},{"period":"6month","weight":0.165},{"period":"1year","weight":0.2625},{"period":"ytd","weight":0.155}],"compareEarnings":[{"period":"1week","weight":0.0107},{"period":"1month","weight":0.0507},{"period":"3month","weight":0.0947},{"period":"6month","weight":0.1069},{"period":"1year","weight":0.2446},{"period":"ytd","weight":0.0734}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"湖南达嘉维康医药产业股份有限公司","boardCode":"AI0051","boardName":"批发业","stockholders":"15969人(较上一季度减少0.26%)","perCapita":"8634股","listingDate":"2021-12-07","address":"湖南省长沙市岳麓区茯苓路30号","registeredCapital":"20540万元","survey":" 湖南达嘉维康医药产业股份有限公司的主营业务是药品、生物制品、医疗器械等产品的分销及零售业务。公司的主要产品是抗肿瘤药、免疫调节用药、心脑血管用药、呼吸系统用药、抗病毒用药、化学药制剂、中成药、生物制药、医疗器械、非药品、中药饮片、清热散结胶囊、脑得生丸、障眼明胶囊、舒筋活血胶囊、清热解毒类、心脑血管类、泌尿类。","listedPrice":12.37},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.34.4","shortVersion":"4.34.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"达嘉维康(301126)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供达嘉维康(301126)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"达嘉维康,301126,达嘉维康股票,达嘉维康股票老虎,达嘉维康股票老虎国际,达嘉维康行情,达嘉维康股票行情,达嘉维康股价,达嘉维康股市,达嘉维康股票价格,达嘉维康股票交易,达嘉维康股票购买,达嘉维康股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"达嘉维康(301126)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供达嘉维康(301126)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}